(Albany, United States) As per DelveInsight’s assessment, globally, the HR Positive/ HER2 Negative Breast Cancer pipeline constitutes 50+ key companies continuously working towards developing 53+ HR Positive/ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the HR Positive/ HER2 Negative Breast Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, HR Positive/ HER2 Negative Breast Cancer clinical trials studies, HR Positive/ HER2 Negative Breast Cancer NDA approvals (if any), and product development activities comprising the technology, HR Positive/ HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the HR Positive/ HER2 Negative Breast Cancer pipeline treatment landscape of the report, click here @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook

 

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• DelveInsight’s HR Positive/ HER2 Negative Breast Cancer Pipeline analysis depicts a robust space with 50+ active players working to develop 53+ pipeline treatment therapies.
• The leading HR Positive/ HER2 Negative Breast Cancer Companies working in the market include Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co.,, Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others
• Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies in the various stages of development include CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others
• On February 2023, CytomX Therapeutics announced a study of phase 2 clinical trials for CX-2009 and CX-072. A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor (HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC.
• On March 2023, AstraZeneca announced a study of phase 3 clinical trials for Dato-DXd, Capecitabine, Gemcitabine, Eribulin, and Vinorelbine.The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator’s choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.
• On May 2023, Olema Pharmaceutical announced a study of phase 1 clinical trials or OP-1250, Ribociclib, and Alpelisib. The dose escalation phase will evaluate 3 to 6 subjects per cohort who are sequentially enrolled and monitored for DLTs during the first cycle of study treatment. Each cohort will be reviewed for safety, PK, and dose-limiting toxicity DLTs. The DLT observation may be extended to 2 cycles.

 

HR Positive/ HER2 Negative Breast Cancer Overview

A breast cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and progesterone, which suggests the cancer cells receive signals from these hormones that promote their growth.

 

To explore more information on the latest breakthroughs in the HR Positive/ HER2 Negative Breast Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight

 

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile

• Camizestrant: AstraZeneca
• Dato-DXd: Daiichi Sankyo, Inc.
• CX-2009: CytomX Therapeutics
• RGT-419B: Regor Therapeutics

 

HR Positive/ HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing therapies for HR Positive/ HER2 Negative Breast Cancer. The companies which have their HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

Request a sample and discover the recent advances in HR Positive/ HER2 Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight

 

HR Positive/ HER2 Negative Breast Cancer Drugs and Companies

• CX-2009: CytomX Therapeutics
• Capecitabine: Daiichi Sankyo Inc
• OP-150: Olema Pharmaceuticals Inc
• Alpelisib: Novartis
• Cyclophosphamide: Eli Lilly and Company

 

HR Positive/ HER2 Negative Breast Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the HR Positive/ HER2 Negative Breast Cancer Therapeutics Market include-

Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co.,, Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.

 

Dive deep into rich insights for drugs for HR Positive/ HER2 Negative Breast Cancer Pipeline, click here for HR Positive/ HER2 Negative Breast Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight

 

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

• Coverage- Global
• HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co.,, Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
• HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others
• HR Positive/ HER2 Negative Breast Cancer Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on HR Positive/ HER2 Negative Breast Cancer Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Dato-DXd: Daiichi Sankyo, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CX-2009: CytomX Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RGT-419B: Regor Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
21. HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
22. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services